Updated: January 26, 2026
How Does Skyrizi Work? Mechanism of Action Explained in Plain English
Author
Peter Daggett

Summarize with AI
Skyrizi blocks IL-23, a key driver of inflammation in psoriasis, Crohn's disease, and more. Here's a plain-English explanation of how it works and why it's so effective.
If you've been prescribed Skyrizi or are considering it, you probably want to understand how it actually works. The short answer: Skyrizi turns down a specific "alarm signal" in your immune system that's been stuck on, causing chronic inflammation. Here's the longer explanation—in plain English.
The Root Problem: An Overactive Immune Signal
In healthy people, the immune system fights off bacteria, viruses, and other threats, then quiets down. In people with psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis, part of the immune system gets stuck in "attack mode"—causing inflammation in skin, joints, or intestines even when there's no real threat.
A key driver of this inappropriate inflammation is a protein called interleukin-23, or IL-23. Think of IL-23 as a "fire alarm" that signals immune cells to release waves of inflammatory chemicals. In these autoimmune diseases, the alarm keeps firing when it shouldn't.
What Is IL-23 and Why Does It Matter?
IL-23 is a cytokine—a small signaling protein made by certain immune cells. It plays a key role in activating and sustaining Th17 cells, a type of T-cell (immune cell) that drives inflammation. When IL-23 is overproduced, it fuels an inflammatory cascade that results in:
Thick, scaly skin plaques in psoriasis
Swollen, painful joints in psoriatic arthritis
Intestinal inflammation, ulcerations, and strictures in Crohn's disease and UC
IL-23 is made up of two subunits: p40 (shared with IL-12) and p19 (unique to IL-23). Skyrizi specifically targets the p19 subunit—a precision approach that blocks IL-23 selectively without affecting IL-12.
How Does Skyrizi Block IL-23?
Skyrizi is a humanized monoclonal antibody—a lab-engineered protein designed to act like a natural antibody, but precisely targeting IL-23. Here's what happens step by step:
You inject Skyrizi under the skin (or receive it by IV infusion for IBD induction). It enters your bloodstream.
Skyrizi molecules travel through your body seeking IL-23 proteins.
Skyrizi binds to the p19 subunit of IL-23 with very high affinity—essentially locking onto IL-23 and blocking it from attaching to the IL-23 receptor on immune cells.
With IL-23 blocked, the downstream inflammatory cascade is interrupted. Th17 cells don't get the "keep fighting" signal. Inflammatory cytokines and chemokines decrease.
Over weeks to months, inflammation in the skin, joints, or intestinal lining diminishes—resulting in clearer skin, reduced joint pain, or improved bowel symptoms.
Why Target IL-23 Instead of Other Pathways?
Earlier biologics like TNF inhibitors (Humira, Enbrel) took a broader approach—blocking TNF, a more general inflammatory signal. IL-23 inhibitors like Skyrizi are more selective, targeting an earlier and more specific step in the inflammatory pathway. Research suggests this precision approach provides durable clinical responses, with many psoriasis patients achieving PASI 90 or PASI 100 (90–100% skin clearance) with Skyrizi.
Additionally, because Skyrizi targets only the p19 subunit of IL-23 (not the p40 subunit shared with IL-12), it avoids disrupting IL-12 signaling, which plays a role in immunity against certain infections and in immune surveillance. This selective targeting is considered an advantage over older dual IL-12/23 inhibitors like Stelara.
How Long Does Skyrizi Take to Work?
For plaque psoriasis, many patients begin to see improvement within 4–12 weeks of starting Skyrizi. In clinical trials, Skyrizi outperformed ustekinumab (Stelara) in speed of onset—44% of Skyrizi patients achieved PASI 90 (90% skin clearance) by week 4 compared with 19% of Stelara patients. Full clinical response typically builds over 16–52 weeks.
For Crohn's disease and UC, the IV induction phase (weeks 0–8) begins the inflammatory reduction process, with clinical response and remission building during the first few months of treatment.
What Happens If You Stop Taking Skyrizi?
Skyrizi is a maintenance therapy, not a cure. Stopping Skyrizi allows IL-23 levels to recover and inflammation to return, typically causing a disease flare. Never stop Skyrizi without discussing it with your doctor—especially if you're considering restarting later, as the impact on re-treatment response should be evaluated.
For an overview of Skyrizi's indications, dosing, and practical information, see What Is Skyrizi? Uses, Dosage, and What You Need to Know in 2026.
Frequently Asked Questions
Skyrizi works by blocking IL-23 (interleukin-23), a protein that drives the inflammatory process behind psoriasis. By binding to the p19 subunit of IL-23, Skyrizi prevents IL-23 from activating immune cells (Th17 cells) that produce the inflammatory signals causing skin cells to multiply rapidly and form plaques. With the inflammatory signal blocked, skin cells can return to a normal growth rate and plaques clear.
Humira (adalimumab) is a TNF inhibitor—it blocks TNF-alpha, a different inflammatory protein. Skyrizi is an IL-23 inhibitor—it blocks IL-23, a more upstream and targeted step in the inflammatory pathway. IL-23 inhibitors like Skyrizi are generally considered to have higher skin clearance rates for psoriasis and a more selective immune mechanism than TNF inhibitors. The right choice depends on your medical history, insurance coverage, and other conditions.
For psoriasis, many patients begin noticing improvement within 4–12 weeks. In clinical trials, 44% of Skyrizi patients achieved PASI 90 (90% skin clearance) by week 4. Full response typically continues to build over 16–52 weeks of treatment. For Crohn's disease and UC, response to the IV induction phase may be noticed within the first 8–12 weeks.
No. Skyrizi is not chemotherapy. It is a biologic immunotherapy—a targeted medication designed to block a specific immune protein (IL-23) that drives inflammation. Chemotherapy drugs work by broadly targeting rapidly dividing cells throughout the body. Skyrizi is highly specific in its mechanism and is used for autoimmune inflammatory conditions, not cancer.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Skyrizi also looked for:
More about Skyrizi
30,038 have already found their meds with Medfinder.
Start your search today.





